Short Antibiotic Treatment in High Risk Febrile Neutropenia
Early Discontinuation of Antibiotics for Unexplained Febrile Neutropenia: a Pilot Randomized Controlled Trial- EASE ANTIBIOTICS Pilot Trial
University Health Network, Toronto
80 participants
Oct 1, 2023
INTERVENTIONAL
Conditions
Summary
Infections are a common complication in patients with cancer. They are a significant cause of complications and death in this population. Patients with cancer and low neutrophil counts due to chemotherapy or disease often have a fever and receive antibiotic treatment. The optimal duration of this treatment is largely unknown. Late, there have been some data suggesting the safety of early discontinuation of antibiotics, though most centers still give more prolonged antibiotic therapies in this situation. The unnecessary prolonged antibiotic use may increase infections with multi-drug-resistant bacteria, which carry a high death rate. Also, an increase in infections caused by Clostridioides difficile and an increase in fungal infections can happen. However, some are concerned that stopping antibiotics while the neutrophil count is still low will result in life-threatening infections. Our study aims to test whether shorter antibiotic treatment in these situations is as safe as more prolonged treatment, resulting in better antibiotic prescription practices in this population.
Eligibility
Inclusion Criteria15
- Age 18 years and older.
- The patient either has acute leukemia (AML, ALL or mixed-phenotypic acute leukemia) and is undergoing induction, re-induction or salvage chemotherapy or undergoing allogeneic HSCT and receiving conditioning chemotherapy and/or radiation.
- Documented febrile neutropenia as defined by the IDSA guidelines \[1\]:
- Single oral temperature of ≥38.3°C or at least two measurements of ≥38.0°C in an interval of ≥1 hour.
- ANC ≤ 0.5x109/L.
- Patient without a clinically or microbiologically documented infection (CDI/MDI).
- We will require the following criteria to rule out infection:
- No focus of infection on a thorough history and physical examination at baseline and daily.
- Negative blood cultures after at least two sets of blood cultures have been taken. For example, the growth of coagulase-negative staphylococci, diphtheroids or Bacillus spp. from a single set will be considered contamination if another set of blood cultures is negative. Therefore, additional blood cultures will be taken in this case.
- Other cultures will be taken as indicated.
- A negative chest XR or CT scan (which will be performed according to the physician's discretion) for patients with symptoms of cough or chest pain.
- The subject will comply with the following criteria:
- Received empirical antibiotics for at least 72 hours AND
- Is afebrile for at least 24 hours AND
- Is still neutropenic (ANC ≤0.5x109/L).
Exclusion Criteria7
- Concurrent participation in another interventional trial.
- The patient has received empirical antibiotics for more than seven days from the onset of the febrile neutropenic episode.
- Septic shock at the onset of the episode or 72 hours (defined as persisting hypotension requiring vasopressors to maintain a MAP ≥ 65 mmHg and having a serum lactate level \> 2 mmol/L despite adequate volume resuscitation).
- Patients with febrile neutropenia secondary to the treatment for solid malignancies, autologous HSCT, CAR-T cell therapy, hematologic malignancies besides acute leukemia when not in the context of allogeneic HSCT, AML treated with consolidation chemotherapy, or ALL treated with intensification and maintenance phase of chemotherapy.
- Clinically or microbiologically documented infections except for probable or proven invasive fungal disease diagnosed a-priori and treated.
- Patients receiving their induction chemotherapy or allogeneic HSCT as outpatients.
- We will not allow the enrollment of patients who have been previously enrolled in this study.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Antibacterial treatment (i.e piperacillin/tazobactam, ceftazidime, cefepime, meropenem, vancomycin, amikacin, tobramycin, ciprofloxacin) will be stopped after 72 hours of treatment and defervescence for 24 hours, irrespective of neutrophil count
Antibacterial treatment (i.e piperacillin/tazobactam, ceftazidime, cefepime, meropenem, vancomycin, amikacin, tobramycin, ciprofloxacin) will be continued until resolution of neutropenia
Locations(4)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05786495